Camurus - Wikipedia Camurus AB (publ) is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap
Camurus AB (CAMX) Stock Price News - Google Finance Get the latest Camurus AB (CAMX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions
US FDA declines to approve Camurus rare hormone disorder drug The U S Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish
Home - Camurus Camurus is committed to improving the lives of patients with severe and chronic diseases Learn more
Camurus AB (publ) (CAMX. ST) - Yahoo Finance Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia
Products - Camurus Camurus’ products are based on our proprietary FluidCrystal® technology and are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery
Eli Lilly taps Camurus tech to advance long-acting obesity meds Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million